{"id":54822,"date":"2025-02-17T17:28:05","date_gmt":"2025-02-17T16:28:05","guid":{"rendered":"https:\/\/helloproject.es\/vigilancia\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\/"},"modified":"2025-02-17T17:28:05","modified_gmt":"2025-02-17T16:28:05","slug":"una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t","status":"publish","type":"post","link":"https:\/\/helloproject.es\/vigilancia\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\/","title":{"rendered":"Una paciente con neuroblastoma lleva 18 a\u00f1os en remisi\u00f3n tras una terapia con CAR-T"},"content":{"rendered":"<p>Una paciente con neuroblastoma ha logrado m\u00e1s de 18 a\u00f1os de remisi\u00f3n sin necesidad de tratamientos adicionales tras recibir terapia con c\u00e9lulas CAR-T. Se trata del caso con mayor tiempo de remisi\u00f3n registrado hasta la fecha para este tipo de tratamiento, seg\u00fan se\u00f1alan los autores de un estudio publicado en Nature Medicine.<\/p>\n<p>La terapia CAR-T consiste en modificar c\u00e9lulas T del sistema inmunitario para que puedan reconocer y eliminar c\u00e9lulas cancerosas. Aunque ha demostrado ser eficaz en algunos tipos de c\u00e1ncer en la sangre, como la leucemia y el linfoma, su efectividad en tumores s\u00f3lidos ha sido m\u00e1s limitada. El neuroblastoma es un c\u00e1ncer pedi\u00e1trico poco frecuente con una alta tasa de reca\u00edda con los tratamientos convencionales.<\/p>\n<p>La terapia CAR-T consiste en modificar c\u00e9lulas T del sistema inmunitario para que puedan reconocer y eliminar c\u00e9lulas cancerosas.<\/p>\n<p>El hallazgo se basa en el seguimiento de un ensayo cl\u00ednico de fase 1 realizado entre 2004 y 2009 en el\u00a0Baylor College of Medicine (EE UU), en el que se administr\u00f3 una terapia CAR-T dirigida contra la prote\u00edna GD2, altamente expresada en el neuroblastoma.<\/p>\n<p><a><\/a><\/p>\n<h2>Seguimiento<\/h2>\n<p><a href=\"https:\/\/www.texaschildrens.org\/find-a-provider\/helen-e-heslop-md-dsc-hon\" target=\"_blank\">Helen Heslop<\/a>, experta en terapia celular y gen\u00e9tica del c\u00e1ncer, y su equipo trataron a 19 ni\u00f1os con\u00a0neuroblastoma. De ellos, 11 ten\u00edan enfermedad activa en el momento de la terapia.\u00a0Aunque el estudio determin\u00f3 que el tratamiento era seguro, 12 pacientes fallecieron entre 2 meses y 7 a\u00f1os despu\u00e9s debido a reca\u00eddas. De los 7 supervivientes, 5 continuaron en seguimiento durante al menos 13 a\u00f1os.<\/p>\n<p>Una de las pacientes ha permanecido m\u00e1s de 18 a\u00f1os en remisi\u00f3n sin recibir ning\u00fan otro tratamiento contra el c\u00e1ncer y ha dado a luz a dos hijos sanos<\/p>\n<p>Una de estas pacientes ha permanecido m\u00e1s de 18 a\u00f1os en remisi\u00f3n sin recibir ning\u00fan otro tratamiento contra el c\u00e1ncer y ha dado a luz a dos hijos sanos. Adem\u00e1s, los investigadores detectaron que las c\u00e9lulas CAR-T persistieron durante al menos 5 a\u00f1os en 5 de los pacientes tratados, incluida la paciente con la remisi\u00f3n prolongada.<\/p>\n<p><a><\/a><\/p>\n<h2>Menor carga tumoral<\/h2>\n<p>Los autores del estudio destacan que los tipos de CAR-T utilizados en este ensayo carec\u00edan de elementos de dise\u00f1o presentes en las versiones modernas, como mol\u00e9culas coestimuladoras.Tambi\u00e9n indican que los pacientes con menor carga tumoral en el momento del tratamiento podr\u00edan beneficiarse m\u00e1s.<\/p>\n<p>Estos hallazgos indican que la terapia CAR-T podr\u00eda proporcionar beneficios a largo plazo en tumores s\u00f3lidos y aportar informaci\u00f3n valiosa sobre su comportamiento biol\u00f3gico.<\/p>\n<p>Referencia:<\/p>\n<p>Che-Hsing Li et al.\u00bbLong-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma\u00bb. <a href=\"https:\/\/www.nature.com\/articles\/s41591-025-03513-0\" target=\"_blank\">Nature Medicine<\/a> (2025).<\/p>","protected":false},"excerpt":{"rendered":"<p>Una paciente con neuroblastoma ha logrado m\u00e1s de 18 a\u00f1os de remisi\u00f3n sin necesidad de tratamientos adicionales tras recibir terapia con c\u00e9lulas CAR-T. Se trata del caso con mayor tiempo de remisi\u00f3n registrado hasta la fecha para este tipo de tratamiento, seg\u00fan se\u00f1alan los autores de un estudio publicado en Nature Medicine. La terapia CAR-T [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[5],"tags":[],"class_list":["post-54822","post","type-post","status-publish","format-standard","hentry","category-noticias"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.9 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Una paciente con neuroblastoma lleva 18 a\u00f1os en remisi\u00f3n tras una terapia con CAR-T - bip4ex<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/helloproject.es\/vigilancia\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Una paciente con neuroblastoma lleva 18 a\u00f1os en remisi\u00f3n tras una terapia con CAR-T\" \/>\n<meta property=\"og:description\" content=\"Una paciente con neuroblastoma ha logrado m\u00e1s de 18 a\u00f1os de remisi\u00f3n sin necesidad de tratamientos adicionales tras recibir terapia con c\u00e9lulas CAR-T. Se trata del caso con mayor tiempo de remisi\u00f3n registrado hasta la fecha para este tipo de tratamiento, seg\u00fan se\u00f1alan los autores de un estudio publicado en Nature Medicine. La terapia CAR-T [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/helloproject.es\/vigilancia\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\/\" \/>\n<meta property=\"og:site_name\" content=\"bip4ex\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-17T16:28:05+00:00\" \/>\n<meta name=\"author\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\\\/\"},\"author\":{\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/person\\\/3767b0619d59a11570372c821f8619ca\"},\"headline\":\"Una paciente con neuroblastoma lleva 18 a\u00f1os en remisi\u00f3n tras una terapia con CAR-T\",\"datePublished\":\"2025-02-17T16:28:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\\\/\"},\"wordCount\":473,\"publisher\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\"},\"articleSection\":[\"Noticias\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\\\/\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\\\/\",\"name\":\"Una paciente con neuroblastoma lleva 18 a\u00f1os en remisi\u00f3n tras una terapia con CAR-T - bip4ex\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#website\"},\"datePublished\":\"2025-02-17T16:28:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Una paciente con neuroblastoma lleva 18 a\u00f1os en remisi\u00f3n tras una terapia con CAR-T\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#website\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\",\"name\":\"bip4ex\",\"description\":\"Vigilancia Tecnol\u00f3gica\",\"publisher\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\",\"name\":\"Helloproject.es\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/bip4ex.png\",\"contentUrl\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/bip4ex.png\",\"width\":322,\"height\":365,\"caption\":\"Helloproject.es\"},\"image\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/person\\\/3767b0619d59a11570372c821f8619ca\",\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/author\\\/luismi\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Una paciente con neuroblastoma lleva 18 a\u00f1os en remisi\u00f3n tras una terapia con CAR-T - bip4ex","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/helloproject.es\/vigilancia\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\/","og_locale":"es_ES","og_type":"article","og_title":"Una paciente con neuroblastoma lleva 18 a\u00f1os en remisi\u00f3n tras una terapia con CAR-T","og_description":"Una paciente con neuroblastoma ha logrado m\u00e1s de 18 a\u00f1os de remisi\u00f3n sin necesidad de tratamientos adicionales tras recibir terapia con c\u00e9lulas CAR-T. Se trata del caso con mayor tiempo de remisi\u00f3n registrado hasta la fecha para este tipo de tratamiento, seg\u00fan se\u00f1alan los autores de un estudio publicado en Nature Medicine. La terapia CAR-T [&hellip;]","og_url":"https:\/\/helloproject.es\/vigilancia\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\/","og_site_name":"bip4ex","article_published_time":"2025-02-17T16:28:05+00:00","author":"Luis Miguel Mej\u00edas Ramos","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Luis Miguel Mej\u00edas Ramos","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/helloproject.es\/vigilancia\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\/#article","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\/"},"author":{"name":"Luis Miguel Mej\u00edas Ramos","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca"},"headline":"Una paciente con neuroblastoma lleva 18 a\u00f1os en remisi\u00f3n tras una terapia con CAR-T","datePublished":"2025-02-17T16:28:05+00:00","mainEntityOfPage":{"@id":"https:\/\/helloproject.es\/vigilancia\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\/"},"wordCount":473,"publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"articleSection":["Noticias"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/helloproject.es\/vigilancia\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\/","url":"https:\/\/helloproject.es\/vigilancia\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\/","name":"Una paciente con neuroblastoma lleva 18 a\u00f1os en remisi\u00f3n tras una terapia con CAR-T - bip4ex","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/#website"},"datePublished":"2025-02-17T16:28:05+00:00","breadcrumb":{"@id":"https:\/\/helloproject.es\/vigilancia\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/helloproject.es\/vigilancia\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/helloproject.es\/vigilancia\/una-paciente-con-neuroblastoma-lleva-18-anos-en-remision-tras-una-terapia-con-car-t\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/helloproject.es\/vigilancia\/"},{"@type":"ListItem","position":2,"name":"Una paciente con neuroblastoma lleva 18 a\u00f1os en remisi\u00f3n tras una terapia con CAR-T"}]},{"@type":"WebSite","@id":"https:\/\/helloproject.es\/vigilancia\/#website","url":"https:\/\/helloproject.es\/vigilancia\/","name":"bip4ex","description":"Vigilancia Tecnol\u00f3gica","publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/helloproject.es\/vigilancia\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/helloproject.es\/vigilancia\/#organization","name":"Helloproject.es","url":"https:\/\/helloproject.es\/vigilancia\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/","url":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","contentUrl":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","width":322,"height":365,"caption":"Helloproject.es"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca","name":"Luis Miguel Mej\u00edas Ramos","url":"https:\/\/helloproject.es\/vigilancia\/author\/luismi\/"}]}},"_links":{"self":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/54822","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/comments?post=54822"}],"version-history":[{"count":0,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/54822\/revisions"}],"wp:attachment":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/media?parent=54822"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/categories?post=54822"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/tags?post=54822"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}